Clinical trial
Efficacy of NicVAX in Smokers Who Want to Quit Smoking
NCT00318383 · National Institute on Drug Abuse (NIDA), NIH · Completed
Key facts
| NCT number | NCT00318383 |
|---|---|
| Title | Efficacy of NicVAX in Smokers Who Want to Quit Smoking |
| Official title | A Phase 2, Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Assess Efficacy of 3'-Aminomethylnicotine-P.Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) in Smokers Who Want to Quit Smoking |
| Lead sponsor | National Institute on Drug Abuse (NIDA), NIH |
| Collaborators | Nabi Biopharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Smoking Cessation |
| Intervention type | Biological |
| Interventions | NicVAX conjugate vaccine, Placebo |
| Enrollment | 313 |
| Start date | May 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Apr 26, 2006 |
| Last update posted | Jan 12, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: